Astex Pharmaceuticals, Inc.
) recently presented data from the phase I portion
(dose-escalation) of the SGI-110-01 study in patients with
intermediate or high risk relapsed or refractory myelodysplastic
syndromes (r/r MDS). The data was presented at the European
Hematology Association (EHA).
15 intermediate or high risk r/r MDS (including chronic
myelomonocytic leukemia) patients were enrolled in the study -
the patients had been treated earlier with either Vidaza
(azacitidine) or Dacogen (decitabine). About 40% of the patients
had undergone treatment with both therapies. Six of the 15
patients achieved an overall response rate of 40%.
SGI-110 is currently in a phase I/II trial for MDS and
acute myeloid leukemia (AML), and phase II trials for
platinum resistant ovarian cancer and liver cancer. The
phase II dose expansion study in patients who are treatment-naive
to prior Vidaza or Dacogen therapy has so far enrolled 40
treatment naïve MDS patients. First data from phase II studies on
platinum-resistant ovarian cancer and liver cancer is expected in
Astex is trying to develop a portfolio of cancer drugs, with
candidates such as AT13387, SGI-110, AT7519, AT9283, and AT13148.
Astex has started phase II studies with AT13387 in patients
with refractory gastrointestinal stromal tumors (GIST),
castration resistant prostate cancer (CPRC), and non-small cell
lung cancer (NSCLC). First data from phase II studies on CRPC and
NSCLC is expected in 2014.
Astex carries a Zacks Rank #3 (Hold). Currently, companies
Anika Therapeutics Inc.
Jazz Pharmaceuticals Public Limited Company
) look well positioned with a Zacks Rank #1 (Strong Buy).
ANIKA THERAPEUT (ANIK): Free Stock Analysis
ASTEX PHARMACT (ASTX): Get Free Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.